BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 - - Provides updated and extended ...
Could the transaction targeted for 2025 trigger a change‑of‑control clause or trigger any anti‑dilution provisions for existing shareholders?
What is the expected impact of the updated guidance on analyst earnings estimates and consensus forecasts?
Are there any regulatory or clinical trial milestones expected in the near term that could materially impact the stock?
28 days ago